SMPD1 and neoplasm: These studies provide strong support for the notion that delivery of antiangiogenic drugs timed to enhance ASMase/ceramide-mediated vascular dysfunction leads to a large increase in oxidative damage to tumor cells after SDRT early during the sequence of events leading to increased tumor cure.